APG Asset Management N.V. Grows Position in Royalty Pharma plc (NASDAQ:RPRX)

APG Asset Management N.V. lifted its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 4.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 382,906 shares of the biopharmaceutical company's stock after buying an additional 17,406 shares during the period. APG Asset Management N.V. owned about 0.06% of Royalty Pharma worth $9,433,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Brooklyn Investment Group increased its holdings in shares of Royalty Pharma by 1,006.9% in the 4th quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 876 shares during the period. Allworth Financial LP increased its position in shares of Royalty Pharma by 417.6% in the 4th quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 877 shares in the last quarter. Riverview Trust Co grew its position in Royalty Pharma by 3,953.3% in the fourth quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 1,186 shares in the last quarter. Fifth Third Bancorp grew its stake in Royalty Pharma by 187.1% in the 4th quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company's stock valued at $39,000 after buying an additional 997 shares during the last quarter. Finally, Rakuten Securities Inc. lifted its position in shares of Royalty Pharma by 160.5% during the 4th quarter. Rakuten Securities Inc. now owns 1,628 shares of the biopharmaceutical company's stock worth $42,000 after buying an additional 1,003 shares during the last quarter. Hedge funds and other institutional investors own 54.35% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. TD Cowen upgraded Royalty Pharma to a "strong-buy" rating in a research note on Tuesday, December 24th. Citigroup reaffirmed a "buy" rating on shares of Royalty Pharma in a research report on Friday, March 28th. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Royalty Pharma currently has a consensus rating of "Buy" and an average target price of $42.50.

Royalty Pharma Stock Up 0.1 %

NASDAQ:RPRX traded up $0.04 on Wednesday, hitting $32.49. 598,578 shares of the company's stock traded hands, compared to its average volume of 3,234,130. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64. The company has a market cap of $18.73 billion, a PE ratio of 22.41, a price-to-earnings-growth ratio of 2.31 and a beta of 0.50. Royalty Pharma plc has a 1 year low of $24.05 and a 1 year high of $34.20. The firm has a 50-day moving average price of $32.54 and a 200-day moving average price of $29.20.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, topping analysts' consensus estimates of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. Equities analysts anticipate that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.